{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:40:16Z","timestamp":1768898416088,"version":"3.49.0"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate the real\u2010world treatment patterns and outcomes for patients with pleural mesothelioma (PM) in the era of immunotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective audit included patients with PM diagnosed within three tertiary referral centers in Queensland, Australia from January 2017 to July 2023. Patient and treatment characteristics and outcomes were recorded. Data was analyzed using descriptive statistics and the Kaplan\u2010Meier survival method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 90 patients were included: 84% were male, the median age was 75 years (range 70\u201379) and 85% had baseline Eastern Group Cooperative Group of 0\u20131. Subtypes included 54% epithelioid, 17% biphasic, 12% sarcomatoid, and 17% unspecified\/unknown. First\u2010line treatment was received by 57\/90 patients (63%) and 33\/90 patients (37%) received the best supportive care (BSC). Chemotherapy was most used (63%) overall, but first\u2010line immunotherapy was more commonly used since ipilimumab\/nivolumab was reimbursed by the Australian Pharmaceutical Benefits Scheme in July 2021. After first\u2010line treatment, only 40% received second\u2010line treatment and 60% received BSC.<\/jats:p><jats:p>12\u2010month overall survival (OS) and progression\u2010free survival for all patients were 53% (95% confidence interval [CI]: 43\u201365) and 25% (95% CI 15\u201340) respectively. 12\u2010month OS was 72%, 64%, and 29% for immunotherapy, chemotherapy, and BSC, respectively. There was no significant difference in survival between chemotherapy and immunotherapy (hazard ratio 1.28, 95% CI: 0.65\u20132.5, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.5).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In our unselected real\u2010world cohort, both chemotherapy and immunotherapy are active against PM, but the prognosis remains guarded. There remains a need for better treatment options, especially in the first\u2010line setting. Enrolment in clinical trials is crucial to improving outcomes in this debilitating disease.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajco.14098","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T03:19:15Z","timestamp":1719026355000},"page":"723-730","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real\u2010world outcomes for patients with pleural mesothelioma: A multisite retrospective cohort study"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8726-4428","authenticated-orcid":false,"given":"Kar Ven Cavan","family":"Chow","sequence":"first","affiliation":[{"name":"The Adem Crosby Cancer Centre Department of Medical Oncology Sunshine Coast Hospital and Health Service  Sunshine Coast Australia"},{"name":"School of Medicine The University of Queensland  Herston Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassie","family":"Turner","sequence":"additional","affiliation":[{"name":"The Adem Crosby Cancer Centre Department of Medical Oncology Sunshine Coast Hospital and Health Service  Sunshine Coast Australia"},{"name":"School of Medicine The University of Queensland  Herston Australia"},{"name":"Department of Medical Oncology Royal Brisbane and Women's Hospital  Herston Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett","family":"Hughes","sequence":"additional","affiliation":[{"name":"School of Medicine The University of Queensland  Herston Australia"},{"name":"Department of Medical Oncology Royal Brisbane and Women's Hospital  Herston Australia"},{"name":"Department of Medical Oncology The Prince Charles Hospital  Chermside Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zarnie","family":"Lwin","sequence":"additional","affiliation":[{"name":"School of Medicine The University of Queensland  Herston Australia"},{"name":"Department of Medical Oncology Royal Brisbane and Women's Hospital  Herston Australia"},{"name":"Department of Medical Oncology The Prince Charles Hospital  Chermside Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Chan","sequence":"additional","affiliation":[{"name":"The Adem Crosby Cancer Centre Department of Medical Oncology Sunshine Coast Hospital and Health Service  Sunshine Coast Australia"},{"name":"School of Medicine The University of Queensland  Herston Australia"},{"name":"School of Medicine and Dentistry Griffith University  Gold Coast Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"issue":"4","key":"e_1_2_8_3_1","first-page":"491","article-title":"Malignant pleural mesothelioma: an epidemiological perspective","volume":"1","author":"Robinson BM","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.5271\/sjweh.1145"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.09.018"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/oemed-2022-108669"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.10.125"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181f1cf2b"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezaa363"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00426"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.008"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8"},{"key":"e_1_2_8_15_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2023.09.239","article-title":"Brief report: real\u2010world toxicity and survival of combination immunotherapy in pleural mesothelioma\u2014RIOMeso","author":"McNamee N","year":"2023","journal-title":"J Thorac Oncol"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100075"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.08.003"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.10.009"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.06.034"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.005"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.01.074"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2014.08.017"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.11.55"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2018.06.026"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00471-X"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.009"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.14098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T03:25:54Z","timestamp":1741749954000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.14098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1111\/ajco.14098"],"URL":"https:\/\/doi.org\/10.1111\/ajco.14098","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]},"assertion":[{"value":"2024-01-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}